Fig. 1
Prophylactic and therapeutic efficacy of mAb H3v-47 in mice. Groups of DBA/2J mice were inoculated i.p. with 10 (high dose) or 1 mg/kg (low dose) of mAb H3v-47 on the day before (day −1, prophylaxis), or on day one (day +1, treatment) after lethal respiratory (i.n. route) challenge with ∼ 6 × 104 focus forming units (FFU) of A/Minnesota/11/2010 × −203 virus and monitored for 10 days. The control groups included mice treated with PBS (mock control) or the previously described mAb CR8020. The protective efficacy of mAbs was assessed by weight change kinetics (a, b), clinical score (c, d), and virus titers in lungs on 4 dpi (e, f). The dotted line (a, b) indicates the IACUC stipulated endpoint for humane euthanasia. Data in a, b shows body weight only for the animals that survived based on actual death between watches or endpoint for euthanasia, and represents the mean value ± SEM, using 10 mice per group. Each group was compared to the PBS-treated group using two-way ANOVA with Dunnett‘s post-hoc test for a, b, and one-way ANOVA with Dunnett‘s post-hoc test for e, f. Dots in e, f indicate individual mice (n = 5 mice per group). The median titer is shown with the line, and the dotted line indicates the limit of detection (LOD). *p < 0.05; **p < 0.01; ***p < 0.001 were considered significant
